Moteur de recherche d’entreprises européennes
Financement de l’UE (6 761 834 €) : Vaincre Goliath : génération de NoveL, approches intégrées et harmonisées à l’échelle internationale pour tester les composés perturbateurs du métabolisme Hor01/01/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Vaincre Goliath : génération de NoveL, approches intégrées et harmonisées à l’échelle internationale pour tester les composés perturbateurs du métabolisme
GOLIATH addresses the work programme topic ‘SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (EDCs)’ by focussing on one of the most urgent regulatory needs, namely the lack of methods for testing EDCs that disrupt metabolism – chemicals collectively referred to as ‘metabolism disrupting chemicals’ (MDCs). MDCs are natural and anthropogenic chemicals that have the ability to promote metabolic changes that can ultimately result in obesity, diabetes and/or fatty liver in humans. GOLIATH will generate the world’s first integrated approach to testing and assessment (IATA) specifically tailored to MDCs. With a focus on the main cellular targets of metabolic disruption – hepatocytes, pancreatic endocrine cells, myocytes and adipocytes - GOLIATH will develop new methods and optimise existing methods that span the entire adverse outcome pathway (AOP) spectrum, using in silico predictive modelling and high throughput screening, (pre-)validated ready-to-use in vitro assays and optimised in vivo toxicity testing guidelines. GOLIATH will provide key information on the endocrine mode of action by which MDCs disrupt metabolic pathways and induce adverse effects on human health by incorporating multi-omics technologies, and translating results from in vitro and in vivo assays to adverse metabolic health outcomes in humans at real life exposures. Given the importance of international acceptance of the developed test methods for regulatory use, GOLIATH will link with ongoing initiatives of the OECD for test method (pre-)validation, IATA and AOP development. With a consortium comprised of world-leading experts in endocrinology, molecular biology, toxicology, epidemiology, test method development, validation and chemical regulation, GOLIATH will be pivotal in the development of an internationally harmonised strategy for testing MDCs, and help to reduce the worldwide rise in metabolic disorders that have reached ‘Goliathan’ proportions.
| Agence Nationale de la Securite Sanitaire de L Alimentation de L Environnement et du Travail | 134 250 € |
| Biopredic International Sàrl | 243 750 € |
| Brunel University London | 224 017 € |
| Department of Health | 497 033 € |
| Hoffmann Sebastian | 75 000 € |
| Imperial College of Science Technology and Medicine | 28 365 € |
| Institut National de la Sante et de la Recherche Medicale | 1 077 695 € |
| Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement | 798 786 € |
| Karolinska Institutet | 402 500 € |
| Linkopings Universitet | 338 288 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 0,00 € |
| THE Regents OF THE University OF California | 339 597 € |
| The University Court of the University of Aberdeen | 220 160 € |
| Umea Universitet | 303 750 € |
| Universidad Miguel Hernandez de Elche | 672 863 € |
| Universiteit Utrecht | 1 268 270 € |
| Vlaamse Instelling Voor Technologisch Onderzoek N.V. | 137 510 € |
https://cordis.europa.eu/project/id/825489
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.